Health Care · Laboratory Analytical Instruments

QTRX Quanterix Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1503274123 filings
Russell 2000

QTRX at a glance

Quanterix Corp (QTRX, SEC CIK 1503274) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Quanterix Corp (QTRX) reported revenue of $138.9 million (up 1.1% from FY2024) and a net loss of $107.2 million. Diluted EPS was -$2.51.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Quanterix Corp (QTRX) shares worth $41.8 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$138.9M
+1.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$41.8M · −1 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 5.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors from the December 31, 2025 Form 10-K
  • Carried-forward business risks could adversely affect financial condition and results of operations
  • Unidentified or currently immaterial risks could adversely affect business performance
  • Common-stock price remains exposed to adverse risk events

Management Discussion & Analysis

  • Revenue $35.0M, down 13% YoY from $40.2M, with product revenue $25.2M and service revenue $9.4M
  • Gross margin 38.6% vs 39.5% YoY, operating margin (64.3%) vs (92.8%), net loss $21.6M vs $33.5M
  • Best line consumables, $20.8M, up 10%; worst line instruments, $4.4M, down 39% YoY
  • Cash and equivalents $35.9M, marketable securities $41.5M; nine-month operating cash outflow $39.4M
  • Outlook: operating losses and negative operating cash flow into 2027; instrument softness from constrained capital funding, grant funding below prior levels

AI summary of the QTRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Everett Cunningham resigned November 18, 2026, leaving both the CEO role and Board seat
  • Departure attributed to another opportunity, with no reported disagreements over operations, disclosures, accounting, or legal matters

Item 7.01: Regulation FD Disclosure

  • CEO Mr. Cunningham resigned, creating leadership-transition risk for Quanterix
  • Mr. Gute appointed as successor, signaling immediate management continuity

Item EX-99.1: Item EX-99.1

  • CEO Everett Cunningham departed immediately to pursue another healthcare opportunity, creating near-term leadership uncertainty
  • Chief Commercial Officer Jim Gute appointed interim President and CEO, leveraging commercial and diagnostics experience
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Earnings Release furnished as Exhibit 99.1, containing the detailed financial results

Item 7.01: Regulation FD Disclosure

  • Quanterix furnished investor presentation slides for its November 9, 2026 earnings call
  • Exhibit 99.2 likely contains earnings-period metrics, guidance, and management commentary relevant to valuation

Item EX-99.2: Item EX-99.2

  • Q3 revenue $35.0M, down 13% YoY but up 6.3% QoQ, indicating early stabilization after prolonged declines
  • Full-year 2026 revenue guidance narrowed to $142M-$146M, maintaining adjusted gross margin guidance of 48%-50%

Item EX-99.1: Item EX-99.1

  • Q3 revenue $35.0M, up 6.3% sequentially but down from $40.2M year over year, signaling early stabilization amid market softness
  • GAAP gross margin 38.6%, while adjusted gross margin improved to 47.4% from 45.9% year over year
Filed Aug 10, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Earnings-call slides furnished as Exhibit 99.2 for August 10, 2026
  • Jim Gute appointed Chief Commercial Officer, signaling a commercial leadership change

Item EX-99.1: Item EX-99.1

  • Q2 revenue $32.9M, up 34% YoY, but below expectations, prompting commercial reorganization and leadership changes
  • 2026 revenue outlook cut to $142–148M from $169–174M, signaling continued academic and pharmaceutical market softness

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results announced for quarter ended June 30, 2026
  • Earnings Release furnished as Exhibit 99.1, containing the detailed financial results and management commentary

Item EX-99.3: Item EX-99.3

  • Jim Gute appointed Chief Commercial Officer, adding 20 years of commercial leadership from GE Healthcare and Exact Sciences
  • Mandate: re-accelerate commercial growth, expand Quanterix’s installed base, and increase new-customer wins

AI summaries of QTRX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for QTRX

Don't miss the next QTRX filing

  • Alerts as it files. A push when QTRX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut QTRX, by share count.
  • Ask anything. An AI agent that reads every QTRX filing and answers with sources.

QTRX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Miller Michael FrancisFNov 15, 2026$2.93
Miller Michael FrancisMNov 15, 2026-
Miller Michael FrancisMNov 15, 2026-
Miller Michael FrancisMNov 15, 2026-
Miller Michael FrancisMNov 15, 2026-
Miller Michael FrancisFNov 15, 2026$2.93
Miller Michael FrancisMNov 15, 2026-
Miller Michael FrancisFNov 15, 2026$2.93

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$137.4M$138.9M
Gross Profit-$83.1M$65.0M
Operating Income--$52.6M-$125.5M
Net Income--$38.5M-$107.2M
Gross Margin-60.5%46.8%
Op. Margin--38.3%-90.4%
Net Margin--28.0%-77.1%
Balance Sheet
Total Assets$425.0M$406.5M$418.8M
Equity$346.9M$330.0M$295.7M
ROE--11.7%-36.2%
Per Share
EPS-$-1.00$-2.51
Cash Flow
Operating CF--$35.2M-$77.2M
CapEx-$3.4M$2.6M

Source: XBRL data in Quanterix Corp (QTRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate QTRX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
QTRX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$41.8M
Q2 202623$50.5M
Q1 202624$47.3M
Q4 202524$98.7M
Q3 202522$86.8M
Q2 202523$94.1M
Q1 202523$69.4M
Q4 202420$112.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 181 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

QTRX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
4Nov 17, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Oct 16, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 17, 2026--
4Sep 16, 2026--
4Sep 1, 2026--
4Aug 20, 2026--
4Aug 19, 2026--
4Aug 17, 2026--
4Aug 14, 2026--
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
SC 13GAug 6, 2026-
4Aug 4, 2026--
4Jul 16, 2026--
4Jul 16, 2026--
4Jul 9, 2026--
4Jul 9, 2026--
4Jul 2, 2026--
4Jul 2, 2026--

Related Health Care companies

All Health Care →

QTRX SEC filings: frequently asked questions

Which institutions hold QTRX stock?

As of September 30, 2026, the largest Quanterix Corp (QTRX) holders among the 13F filers tracked by SignalX were BlackRock ($14.0 million), Vanguard Capital Management LLC ($6.7 million), State Street Corp ($3.3 million), AQR Capital Management ($2.9 million), Citadel Advisors LLC ($2.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was QTRX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Quanterix Corp (QTRX) reported revenue of $138.9 million (up 1.1% from FY2024) and a net loss of $107.2 million. Diluted EPS was -$2.51. The figures come from the XBRL data in the 10-K.

What did QTRX report in its latest 8-K?

Quanterix Corp (QTRX) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). CEO Everett Cunningham resigned November 18, 2026, leaving both the CEO role and Board seat.

What are the latest QTRX SEC filings?

Quanterix Corp (QTRX) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 17, 2026.

What is QTRX's SEC CIK number?

Quanterix Corp (QTRX)'s SEC Central Index Key (CIK) is 1503274. EDGAR lists every QTRX filing under that number.

Ask anything about QTRX

The research agent reads QTRX's filings, financials, insider trades and 13F holders, then answers with sources.